Annals of Oncology Advance Access originally published online on May 22, 2008
Annals of Oncology 2008 19(10):1802-1809; doi:10.1093/annonc/mdn363
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Phase I and Pharmacokinetics |
A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies
1 Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA
2 Department of Oncology, Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Raritan, NJ, USA
* Correspondence to: Dr M. von Mehren, Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA. Tel: +1-215-728-2674; Fax: +1-215-728-3639; E-mail: margaret.vonmehren{at}fccc.edu
Background: To determine the maximum tolerated dose (MTD), safety, potential pharmacokinetic (PK) interactions, and effect on liver histology of trabectedin in combination with pegylated liposomal doxorubicin (PLD) for advanced malignancies.
Patients and methods: Entry criteria for the 36 patients included normal liver function, prior doxorubicin exposure <250 mg/m2, and normal cardiac function. A 1-h PLD (30 mg/m2) infusion was followed immediately by one of six trabectedin doses (0.4, 0.6, 0.75, 0.9, 1.1, and 1.3 mg/m2) infused over 3 h, repeated every 21 days until evidence of complete response (CR), disease progression, or unacceptable toxicity. Plasma samples were obtained to assess PK profiles.
Results: The MTD of trabectedin was 1.1 mg/m2. Drug-related grade 3 and 4 toxic effects were neutropenia (31%) and elevated transaminases (31%). Six patients responded (one CR, five partial responses), with an overall response rate of 16.7%, and 14 had stable disease (less than a 50% reduction and less than a 25% increase in the sum of the products of two perpendicular diameters of all measured lesions and the appearance of no new lesions) >4 months (39%). Neither drug had its PK affected significantly by concomitant administration compared with trabectedin and PLD each given as a single agent.
Conclusion: Trabectedin combined with PLD is generally well tolerated at therapeutic doses of both drugs in pretreated patients with diverse tumor types and appears to provide clinical benefit. These results support the need for additional studies of this combination in appropriate cancer types.
Key words: ET-743, ovarian cancer, pegylated liposomal doxorubicin (PLD), sarcomas, trabectedin
Received for publication February 1, 2008. Revision received April 23, 2008. Accepted for publication April 24, 2008.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. A.B. van Waterschoot, R. M. Eman, E. Wagenaar, C. M.M. van der Kruijssen, H. Rosing, J. H. Beijnen, and A. H. Schinkel ABCC2, ABCC3, and ABCB1, but not CYP3A, Protect against Trabectedin-Mediated Hepatotoxicity Clin. Cancer Res., December 15, 2009; 15(24): 7616 - 7623. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. K. Chuk, F. M. Balis, and E. Fox Trabectedin Oncologist, August 1, 2009; 14(8): 794 - 799. [Full Text] [PDF]
|
|